Retatrutide

Overview

Retatrutide is a synthetic peptide that agonises three receptors: GLP-1, GIP and glucagon. It represents the current extension of a design progression running through this catalogue — single agonist, dual agonist, triple agonist — and the third receptor is the one that makes it interesting, because on the face of it that receptor should not be there.

It is also the least established of the three. Semaglutide and tirzepatide are approved medicines with multi-year outcome data. Retatrutide is not approved anywhere.

Chemical identity

• Also known as: LY3437943
• CAS number: 2381089-83-2
• Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular weight: 4731.33 g/mol
• Classification: Triple GIP, GLP-1 and glucagon receptor agonist
• Length: 39 residues plus the acylation chain
• Appearance: White lyophilised powder

Like the other compounds in this family, it is a large acylated peptide well beyond the size at which a structural depiction stays readable, and it contains no sulfur — no cysteine, no methionine.

Three receptors

The GLP-1 and GIP components are described in detail on the semaglutide and tirzepatide pages, and behave as they do there: glucose-dependent insulin secretion, slowed gastric emptying, satiety signalling.

The glucagon receptor is the addition, and it is worth understanding why its inclusion looks wrong before explaining why it is not.

Why add glucagon?

Glucagon is, in the standard account, insulin’s opposite. Released by pancreatic alpha cells when blood glucose falls, it instructs the liver to break down glycogen and produce glucose. Agonising its receptor raises blood sugar — seemingly the last thing a metabolic compound should do.

That account is incomplete. Glucagon also increases energy expenditure and promotes hepatic fat oxidation. Those effects have been recognised for decades and have long made glucagon receptor agonism theoretically attractive for metabolic research — and practically unusable, because the glycaemic penalty outweighed the benefit.

The reasoning behind a triple agonist is that the incretin components solve that problem. GLP-1 and GIP agonism drive glucose-dependent insulin secretion, which counteracts glucagon’s effect on blood sugar, while glucagon’s contribution to energy expenditure and hepatic lipid handling is retained. Each component covers the others’ liability.

Whether the balance is right is precisely what the trials are establishing. The ratio between the three activities is a design parameter, as it is for tirzepatide’s two, and there is no reason to assume the first ratio tried is the best one.

One, two, three

The three compounds together make a legible progression, which is part of why this family is interesting to study as a set rather than individually:

• Semaglutide — GLP-1 alone. Built on GLP-1. Approved.
• Tirzepatide — GIP and GLP-1. Built on GIP. Approved.
• Retatrutide — GIP, GLP-1 and glucagon. Investigational.

All three use the same durability strategy: non-standard amino acids to resist DPP-4 cleavage, and a fatty acid chain giving reversible albumin binding for weekly administration. The engineering that makes them last is essentially solved; what differs between them is which receptors they engage and in what proportion.

That is a useful thing to notice. This family is no longer about making peptides survive in circulation — that problem was addressed by albumin-binding chemistry more than a decade ago. It is about receptor combination.

Research record

Substantial for a compound at this stage, and entirely from the last few years:

• Discovery and pharmacology. Coskun and colleagues published the characterisation of the molecule, covering receptor activity at all three targets and early clinical work.
• Obesity. A randomised phase 2 trial reported by Jastreboff and colleagues examined effects on body weight across a dose range.
• Type 2 diabetes. A separate randomised phase 2 trial examined glycaemic endpoints, with both placebo and active comparators.

Phase 3 work is ongoing. What that means for anyone reading the literature is that the current evidence is phase 2: real, randomised, controlled, and shorter and smaller than the programmes behind the approved compounds in this family.

Reported observations

Trial reports describe gastrointestinal effects as the most common finding — nausea, diarrhoea, vomiting, constipation — dose-related and concentrated during escalation, the pattern shared across this class.

Two observations are more specific to the glucagon component and are worth attention rather than being folded into the general list. Increases in heart rate have been reported, and effects on glucose handling differ from what a pure incretin agonist produces — unsurprising given that one of the three receptors raises hepatic glucose output by design.

The honest position on longer-term effects is that they are not yet characterised. This is not the same as saying none exist. Phase 2 trials are not sized or lengthened to detect infrequent or slow-developing effects, and for the approved compounds in this family that information came from programmes considerably larger and longer than anything retatrutide has completed.

Regulatory status

Retatrutide is not an approved medicine in any jurisdiction. It is an investigational compound in clinical development.

That distinguishes it from semaglutide and tirzepatide in a way that matters. For those two, an approved product exists and the honest statement is that research material is not a substitute for it. For retatrutide there is no approved product to be a substitute for — and the correct inference is not that this makes research material more appropriate for use, but that even less is known about the compound than about the ones that have completed the process.

Handling, reconstitution and storage

• Lyophilised storage: sealed, refrigerated, protected from light. Freeze for long-term storage.
• No oxidation-prone residues. No sulfur in the formula means neither methionine nor cysteine, removing the commonest chemical degradation route.
• Surface activity from the acylation. As with the others in this family, the fatty acid chain promotes adsorption onto container surfaces and foaming on agitation. Do not shake.
• Reconstitution: add diluent slowly down the vial wall and allow the powder to dissolve undisturbed.
• After reconstitution: refrigerate, protect from light, minimise freeze–thaw cycles.
• Concentration: our peptide reconstitution calculator converts vial quantity, diluent volume and syringe size into concentration per unit.

Purity and analytical verification

A 39-residue acylated peptide with non-standard amino acids is a demanding synthesis, and the analytical picture matches tirzepatide’s closely.

Mass confirmation is the essential check. Failed or partial acylation removes a large, well-defined mass, and an unacylated backbone would have a half-life of minutes rather than days — a different compound in every way that matters. The measured mass should be compared against the expected 4,731 g/mol.

There is an additional consideration specific to a newer compound. Reference standards and published analytical methods are less established for investigational molecules than for approved ones, and there is correspondingly less independent material against which a supplier’s figures can be checked. That is a reason to weight the certificate more heavily, not less — and to prefer suppliers who identify the batch and the method rather than reporting a bare percentage.

We publish third-party certificates of analysis by batch.

References

• Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022. PMID 35985340
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023. PMID 37366315
• Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial. The Lancet, 2023. PMID 37385280

Summary

Retatrutide (LY3437943) is a triple GIP, GLP-1 and glucagon receptor agonist, CAS 2381089-83-2, molecular formula C₂₂₁H₃₄₂N₄₆O₆₈, molecular weight 4,731.33 g/mol. The glucagon component is the novel element: glucagon raises blood glucose, which would ordinarily disqualify it, but it also increases energy expenditure and hepatic fat oxidation, and the incretin components offset the glycaemic effect. Durability comes from the same DPP-4-resistant substitutions and reversible albumin binding used across this family. Published evidence is phase 2 — randomised and controlled, but shorter and smaller than the programmes behind the approved compounds it is compared with — and it is not approved in any jurisdiction.

For laboratory research use only. Not for human consumption. This material is not a drug, food, or cosmetic and may not be sold or used for any purpose other than in vitro or non-human laboratory research. References to clinical studies describe the published scientific literature and are not guidance for use.